Vicente Planelles, PhD, is a Professor in the Department of Pathology at the University of Utah and a member of the Cell Response and Regulation Program at Huntsman Cancer Institute.
A major goal of his research is to understand, at a molecular level, the events that lead to apoptosis, the normal process of cell death. In cancer, cells do not die normally.
Planelles earned a bachelor's degree from the Universidad Complutense, Spain, and a PhD from the University of California, Davis.
University of California
- Trypsteen W, White CH, Mukim A, Spina CA, De Spiegelaere W, Lefever S, Planelles V, Bosque A, Woelk CH, Vandekerckhove L, Beliakova-Bethell N (2019). Long non-coding RNAs and latent HIV - A search for novel targets for latency reversal. PLoS One, 14(11), e0224879.
- Read DF, Atindaana E, Pyaram K, Yang F, Emery S, Cheong A, Nakama KR, Burnett C, Larragoite ET, Battivelli E, Verdin E, Planelles V, Chang CH, Telesnitsky A, Kidd JM (2019). Stable integrant-specific differences in bimodal HIV-1 expression patterns revealed by high-throughput analysis. PLoS Pathog, 15(10), e1007903.
- Rodrguez-Mora S, Spivak AM, Szaniawski MA, Lpez-Huertas MR, Alcam J, Planelles V, Coiras M (2020). Tyrosine Kinase Inhibition: a New Perspective in the Fight against HIV. Curr HIV/AIDS Rep, 16(5), 414-422.
- Hotter D, Bosso M, Jnsson KL, Krapp C, Strzel CM, Das A, Littwitz-Salomon E, Berkhout B, Russ A, Wittmann S, Gramberg T, Zheng Y, Martins LJ, Planelles V, Jakobsen MR, Hahn BH, Dittmer U, Sauter D, Kirchhoff F (2019). IFI16 Targets the Transcription Factor Sp1 to Suppress HIV-1 Transcription and Latency Reactivation. Cell Host Microbe, 25(6), 858-872.e13.
- Morton EL, Forst CV, Zheng Y, DePaula-Silva AB, Ramirez NP, Planelles V, DOrso I (2018). Transcriptional Circuit Fragility Influences HIV Proviral Fate. Cell Rep, 27(1), 154-171.e9.
- Szaniawski MA, Spivak AM, Bosque A, Planelles V (2018). Sex Influences SAMHD1 Activity and Susceptibility to Human Immunodeficiency Virus-1 in Primary Human Macrophages. J Infect Dis, 219(5), 777-785.
- Spivak AM, Nell RA, Petersen M, Martins L, Sebahar P, Looper RE, Planelles V (2018). Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal. Antimicrob Agents Chemother, 62(11).
- Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A (2018). Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. JCI Insight, 3(19).
- Macedo AB, Resop RS, Martins LJ, Szaniawski MA, Sorensen ES, Spivak AM, Nixon DF, Jones RB, Planelles V, Bosque A (2018). Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus. AIDS Res Hum Retroviruses, 34(9), 769-777.
- Planelles V (2018). Inhibition of HIV-1 by a mutant tRNA. U.S. Patent No. International Patent No. PCT/US01/17458. Washington, D.C.:U.S. Patent and Trademark Office.
- Planelles V (2018). Inhibition of HIV-1 by a mutant tRNA. U.S. Patent No. 08/866,116. Washington, D.C.:U.S. Patent and Trademark Office.
- Planelles V (2013). Triazol-1-OL analogs as anti-viral latency drugs.
- Planelles V, Bosque A (2010). Methods and composition relating to viral latency. U.S. Patent No. 2010/0291067 A1. Washington, D.C.:U.S. Patent and Trademark Office.
- Chen ISY, Jowett JBM, Planelles V (1998). Screening assay for anti-HIV drugs. U.S. Patent No. 5,721,104. Washington, D.C.:U.S. Patent and Trademark Office.
- Chen ISY, Jowett JBM, Planelles V (1997). Screening assay for anti-HIV drugs using the Vpr gene. U.S. Patent No. 5,639,619. Washington, D.C.:U.S. Patent and Trademark Office.